Maximum Dose of Tirzepatide for Weight Loss

The maximum weekly dose of tirzepatide for weight loss based on clinical trial data is 15 mg subcutaneously once weekly. 1, 2, 3

FDA-Approved Dosing

Tirzepatide was FDA-approved for obesity treatment in November 2023, with maintenance doses of 5 mg, 10 mg, and 15 mg once weekly. 1, 2, 3
The 15 mg weekly dose represents the maximum approved and studied dose for weight management. 1, 3

Initiate tirzepatide at 2.5 mg subcutaneously once weekly for the first 4 weeks, then increase by 2.5 mg every 4 weeks until reaching the maintenance dose of 10 mg or 15 mg. 3
The 2.5 mg starting dose is not an FDA-approved maintenance dose but serves as the initial titration step to minimize gastrointestinal adverse effects. 3
The 4-week titration interval is essential and non-negotiable—accelerating dose escalation significantly increases gastrointestinal side effects (nausea, vomiting, diarrhea) and treatment discontinuation rates. 3

At 72 weeks, the 15 mg weekly dose produces the greatest weight reduction:

15 mg weekly: 20.9% mean weight loss (with 57% of participants achieving ≥20% weight loss and approximately 40% achieving ≥25% weight loss). 1, 3, 4
10 mg weekly: 19.5% mean weight loss (with 50% achieving ≥20% weight loss). 1, 3, 4
5 mg weekly: 15.0% mean weight loss. 1, 4

Extended therapy up to 88 weeks can achieve up to 26% weight reduction with the 15 mg dose. 3

A meta-analysis of 12,371 adults with overweight or obesity without diabetes demonstrated that 15 mg weekly tirzepatide was associated with 5.1% greater weight loss compared to 2.4 mg weekly subcutaneous semaglutide (mean difference 5.1%; 95% CI, 0.6%-9.8%). 1
The same analysis showed 15 mg weekly tirzepatide produced 13.0% greater weight loss compared to 3 mg daily subcutaneous liraglutide (95% CI, 8.8%-17.4%). 1

Gastrointestinal adverse events (nausea, vomiting, diarrhea) are the most common side effects, occurring primarily during dose escalation. 1, 3, 4
Most gastrointestinal events are mild to moderate in severity; treatment discontinuation due to adverse events occurred in 6.2% of participants receiving 15 mg tirzepatide versus 2.6% with placebo in the SURMOUNT-1 trial. 4
Tirzepatide increases the risk of gallbladder or biliary disease, particularly during rapid weight loss in the first few months of therapy. 3
Patients should be counseled to eat smaller meals, avoid high-fat foods, and stop eating when feeling full to mitigate gastrointestinal symptoms. 3

The 15 mg maximum dose was established through the SURMOUNT clinical trial program:

SURMOUNT-1 (n=2,539): Randomized adults with obesity without diabetes to 5 mg, 10 mg, or 15 mg tirzepatide versus placebo for 72 weeks, demonstrating dose-dependent weight loss with the 15 mg dose achieving 20.9% mean reduction. 1, 4
SURMOUNT-4 (n=670): Participants who achieved weight loss on tirzepatide (maximum tolerated dose of 10 or 15 mg) were randomized to continue tirzepatide or switch to placebo, showing that continued treatment with the maximum dose maintained and augmented weight reduction (25.3% overall reduction from baseline to week 88). 5

No clinical trial data support exceeding the 15 mg weekly dose—this represents both the maximum studied and maximum FDA-approved dose for weight management. 1, 3
If tirzepatide therapy is interrupted for any duration, patients must restart at 2.5 mg and repeat the full titration schedule to avoid severe gastrointestinal intolerance. 3
Abrupt discontinuation of tirzepatide commonly results in regaining 50-66% of lost weight within one year, underscoring the need for long-term treatment. 3, 6, 5